NeuroThera Labs Inc. (TSXV: NTLX) announced today that it has closed the acquisition of a majority stake in CliniQuantum Ltd., a private Israeli technology company that applies quantum simulation and Monte Carlo methods to clinical trial data analysis. The transaction, initially announced on March 10, 2026, and amended on April 30, 2026, involved the purchase of approximately 54.01% of CliniQuantum's outstanding ordinary shares.
Under the terms of the share purchase agreement, NeuroThera issued 56,600,000 common shares to the selling shareholders, with an aggregate deemed value of approximately $9,459,954.20, based on the 20-day volume weighted average trading price on the TSX Venture Exchange. No cash consideration was paid. Additionally, the selling shareholders may receive earn-out payments of up to US$2,500,000 over three years, contingent on achieving milestones related to patent filings and fundraising proceeds.
CliniQuantum's platform aims to improve the precision of clinical trial outcomes by identifying patient subpopulations that respond to investigational therapies. NeuroThera believes the acquisition complements its existing clinical development programs in central nervous system disorders and provides exposure to quantum technologies in life sciences. This move comes as the biotech industry increasingly explores advanced computational methods to enhance drug development efficiency.
The transaction involved non-arm's length parties, as Amitay Weiss, a director of SciSparc Ltd. and SciSparc Nutraceuticals Inc., NeuroThera's majority owner, also serves as a director of Quantum X Labs Ltd., which holds the remaining CliniQuantum shares. The deal received final acceptance from the TSX Venture Exchange.
The 56,600,000 consideration shares have been placed into escrow under a TSXV Form 5D Escrow Agreement, with releases scheduled over 36 months. The shares are subject to a statutory hold period expiring on October 2, 2026. Finder's fees of 2,829,999 common shares were also issued to arm's length finders.
This acquisition signals a growing trend of integrating quantum computing into clinical research, potentially accelerating the identification of effective treatments for underserved conditions. For investors, the deal offers exposure to emerging quantum applications in healthcare, though risks remain due to CliniQuantum's early stage and reliance on licensed technology. The company's forward-looking statements caution that actual results may differ materially from projections.
More details are available in the original release on NewMediaWire and the company's filings on SEDAR+.
